+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-11-14Number of Pages: 102

Uterine Fibroids Treatment Market (Procedure Type - Endometrial Ablation, MRI Guided Procedures (Percutaneous Laser Ablation and Transcutaneous Focused Ultrasound), Hysterectomy (Abdominal, Vaginal, Laparoscopic, Robotic, and Hysteroscopic Morcellation), Myomectomy (Open, Laparoscopic, and Robotic), Uterine Artery Embolization, and Radiofrequency Ablation; End User - Hospitals and Ambulatory Surgical Centers - U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016 - 2024

U.S. Uterine Fibroids Market: Snapshot

The high prevalence of uterine fibroids across the U.S. has created a significant demand for uterine fibroid treatments across the countries. The growing public concern about the occurrence of uterine fibroids, which are also called uterine leiomyoma, have propelled the demand for treatments and solutions to alleviate the pain, excessive bleeding, and pelvic discomfort.

According to the report by Transparency Market Research, the U.S. uterine fibroid treatment market is anticipated to be worth US$273.6 mn in 2024 as compared to US$211.6 mn in 2015. Analysts anticipate that the overall market will expand at CAGR of 2.9% from 2016 to 2024.

us uterine fibroid treatment market

Rising Prevalence of Uterine Fibroids amongst Younger Women Drives Market

These fibroids are non-cancerous tumors and are generally seen amongst women who are in the reproductive age. There are 20%-40% chances of women in developing uterine fibroids during their reproductive ages. These fibroids can swell up to cause pain and make the body look like it is pregnant. Unfortunately, there are no symptoms that indicate the formation of fibroids, which makes it difficult to prevent them from happening. The U.S. Department of Health and Human Services Office on Women’s Health states that around 30% of the women population around the age 35 suffer from uterine fibroids, while the chances come to 20%-80% by the time women reach the age of 50. The prevalence of uterine fibroids is comparatively higher amongst the African American women who are known to develop these fibroids at a younger age that most of the other women.

The U.S. uterine fibroids market offer a wide array of treatments for uterine fibroids. In most of the cases, medical therapy is used for shrinking the fibroids much before performing a surgical procedure. Drugs that shrink fibroids include gonadotropin-releasing hormones, which often result in menopause-like symptoms are widely available in the market. Drugs that designed to block the hormone progesterone can often slowdown the growth of fibroids. Several healthcare professionals also prescribe over-the-counter medications to contain the pain and bleeding.

Hysterectomy Gains Preference over Others

Of the various procedures used for treating uterine fibroids, hysterectomy is the most popular one. The hysterectomy segment is further divided into abdominal hysterectomy, laparoscopic hysterectomy, vaginal hysterectomy, robotic hysterectomy, and hysteroscopic morcellation. Analysts anticipate that hysterectomy is expected to be the major segment in the country and the leading revenue generator. The procedure removes the uterus to tackle the symptoms such as chronic pelvic pain, disrupted lifestyle, and uncontrollable menstrual bleeding. The American Congress of Obstetricians and Gynecologists states that about 600,000 hysterectomy procedures are performed each year. Of these surgeries, one in every third case is due indications of fibroids. However, the growth of this segment is being challenged due to the introduction of several alternatives to the life-altering procedure.

The end users of uterine fibroids treatments are hospitals and ambulatory surgical centers. Out of these, the hospitals segment is leading the U.S. market as it is well-equipped to handle emergencies and complicated matters pertaining to uterine fibroids. The growing concerns about uterine fibroids, physical morbidity, poor quality of life, rising disposable incomes, and well-established healthcare infrastructure are contributing towards the rise of the U.S. uterine fibroids market in the coming years.

Some of the important players operating in the U.S. uterine fibroids market are Blue Endo, Richard Wolf Medical Instruments, Cooper Surgical, Halt Medical, Inc, LiNA Medical USA, Karl Storz, Merit Medical Systems, Richard Wolf GmbH, Olympus Corporation, Halt Medical, Inc., and Boston Scientific Corporation.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : U.S. Uterine Fibroid Treatment Market

4. Market Overview
     4.1. Introduction
             4.1.1. Industry Evolution / Developments
     4.2. Overview
     4.3. Key Market Indicators
     4.4. Market Dynamics
             4.4.1. Drivers
             4.4.2. Restraints
             4.4.3. Opportunity
     4.5. U.S. Uterine Fibroid Treatment Market Analysis and Forecasts, 2014–2024
             4.5.1. Market Revenue Projections, 2014–2024
     4.6. Disease Epidemiology and Treatment
     4.7. Porter’s Five Force Analysis
     4.8. Market Outlook

5. U.S. Uterine Fibroid Treatment Market Analysis and Forecasts, by Procedure Type, 2016–2024
     5.1. Introduction & Definition
     5.2. Key Findings/Developments
     5.3. Market Value (US$ Mn) Forecast, by Procedure Type, 2016–2024
             5.3.1. Endometrial Ablation
             5.3.2. MRI Guided Procedures
             5.3.3. Hysterectomy
             5.3.4. Myomectomy
             5.3.5. Uterine Artery Embolization 
             5.3.6. Radiofrequency Ablation
             5.3.7. Others
     5.4. Procedure Type Comparison Matrix
     5.5. Market Attractiveness, by Procedure Type, 2016–2024

6. U.S. Uterine Fibroid Treatment Market Analysis and Forecasts, by Procedure Type Sub-segment, 2016–2024
     6.1. Market Value (US$ Mn) Forecast, by Procedure Type Sub-segment, 2016–2024
             6.1.1. MRI Guided Procedures
                      6.1.1.1. MRI-guided Percutaneous Laser Ablation
                      6.1.1.2. MRI Guided Transcutaneous Focused Ultrasound
             6.1.2. Hysterectomy
                      6.1.2.1. Abdominal Hysterectomy
                      6.1.2.2. Vaginal Hysterectomy
                      6.1.2.3. Laparoscopic Hysterectomy
                      6.1.2.4. Robotic Hysterectomy
                      6.1.2.5. Hysteroscopic Morcellation
             6.1.3. Myomectomy
                      6.1.3.1. Open Myomectomy
                      6.1.3.2. Laparoscopic Myomectomy
                      6.1.3.3. Robotic Myomectomy
     6.2. Market Attractiveness, by Procedure Type Sub-segment, 2016–2024

7. U.S. Uterine Fibroid Treatment Market Analysis and Forecasts, by End-user, 2016–2024
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Market Value (US$ Mn) Forecast, by End-user, 2016–2024
             7.3.1. Hospitals
             7.3.2. Ambulatory Surgical Centers
     7.4. End-user Comparaison Matrix
     7.5. Market Attractiveness, by End-user 

8. U.S. Uterine Fibroid Treatment Procedure Volume Analysis and Forecasts – 2010–2015 & 2016–2024
     8.1. Endometrial Ablation
     8.2. MRI Guided Procedures
             8.2.1. MRI-guided Percutaneous Laser Ablation
             8.2.2. MRI Guided transcutaneous focused Ultrasound
     8.3. Hysterectomy
             8.3.1. Abdominal Hysterectomy
             8.3.2. Vaginal Hysterectomy
             8.3.3. Laparoscopic Hysterectomy
             8.3.4. Robotic Hysterectomy
             8.3.5. Hysteroscopic Morcellation
     8.4. Myomectomy
             8.4.1. Open Myomectomy
             8.4.2. Laparoscopic Myomectomy
             8.4.3. Robotic Myomectomy
     8.5. Uterine Artery Embolisation
     8.6. Radiofrequency Ablation
     8.7. Others

9. Competition Landscape
     9.1. Market Player – Competition Matrix (By Tier and Size of companies)
     9.2. Market Share Analysis, by Company (2015)
     9.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
             9.3.1. Blue Endo
             9.3.1. Company Overview
             9.3.2. Financial Overview
             9.3.3. Business Strategies
             9.3.2. Boston Scientific Corporation
             9.3.1. Company Overview
             9.3.2. Financial Overview
             9.3.3. Business Strategies
             9.3.3. CooperSurgical, Inc.
             9.3.1. Company Overview
             9.3.2. Financial Overview
             9.3.3. Business Strategies
             9.3.4. Karl Storz
             9.3.1. Company Overview
             9.3.2. Financial Overview
             9.3.3. Business Strategies
             9.3.5. Halt Medical, Inc.
             9.3.1. Company Overview
             9.3.2. Financial Overview
             9.3.3. Business Strategies
             9.3.6. LiNA Medical USA
             9.3.1. Company Overview
             9.3.2. Financial Overview
             9.3.3. Business Strategies
             9.3.7. Merit Medical Systems
             9.3.1. Company Overview
             9.3.2. Financial Overview
             9.3.3. Business Strategies
             9.3.8. Olympus Corporation
             9.3.1. Company Overview
             9.3.2. Financial Overview
             9.3.3. Business Strategies
             9.3.9. Richard Wolf GmbH
             9.3.1. Company Overview
             9.3.2. Financial Overview
             9.3.3. Business Strategies

List of Figures

Figure 01: US Uterine Fibroid Treatment Market Revenue (US$ Mn) Forecast, 2014–2024
Figure 02: U.S. Endometrial Ablation Market Revenue (US$ Mn), 2014–2024
Figure 03: U.S. MRI Guided Procedures Market Revenue (US$ Mn), 2014–2024
Figure 04: U.S. Hysterectomy Market, Revenue (US$ Mn), 2014–2024
Figure 05: U.S. Myomectomy Market, Revenue (US$ Mn), 2014–2024
Figure 06: U.S. Endometrial Ablation Devices Market, Revenue (US$Mn), 2014–2024
Figure 07: U.S. Radiofrequency Ablation Devices Market, Revenue (US$ Mn), 2014–2024
Figure 08: U.S. Other Procedure Market, Revenue (US$Mn), 2014–2024
Figure 09: U.S. Uterine Fibroid Market Attractiveness Analysis, by Procedure Type, 2016 – 2024
Figure 10: U.S. MRI-guided Percutaneous Laser Ablation Market Revenue (US$ Mn), 2014–2024
Figure 11: U.S. MRI guided Transcutaneous Focused Ultrasound Market Revenue (US$ Mn), 2014–2024
Figure 12: U.S. Abdominal Hysterectomy Market, Revenue (US$ Mn), 2014–2024
Figure 13: U.S. Vaginal Hysterectomy Market, Revenue (US$ Mn), 2014–2024
Figure 14: U.S. Laparoscopic Hysterectomy Market, Revenue (US$ Mn), 2014–2024
Figure 15: U.S. Robotic Hysterectomy Market, Revenue (US$ Mn), 2014–2024
Figure 16: U.S. Hysteroscopic Morcellation Market, Revenue (US$ Mn), 2014–2024
Figure 17: U.S. Open Myomectomy Market, Revenue (US$ Mn), 2014–2024
Figure 18: U.S. Laparoscopic Myomectomy Market, Revenue (US$ Mn), 2014–2024
Figure 19: U.S. Robotic Myomectomy Market, Revenue (US$ Mn), 2014–2024
Figure 20: U.S. Uterine Fibroid Market Attractiveness Analysis, by Procedure Type Sub-segment, 2016 – 2024
Figure 21: U.S. Hospitals Market, Revenue (US$ Mn), 2014–2024
Figure 22: U.S. Ambulatory Surgical Centers Market, Revenue (US$ Mn), 2014–2024
Figure 23: U.S. Uterine Fibroid Market Attractiveness Analysis, by End-user, 2016 – 2024
Figure 24: U.S. Uterine Fibroid Treatment Market Share Analysis, by Company (2015)

List of Tables

Table 01: U.S. Uterine Fibroid Treatment Market Size (US$ Mn) Forecast, by Procedure Type, 2014–2024
Table 02: U.S. Uterine Fibroid Treatment Market Size (US$ Mn) Forecast, by MRI Guided Procedure Type, 2014–2024
Table 03: U.S. Uterine Fibroid Treatment Market Size (US$ Mn) Forecast, by Hysterectomy Procedure Type, 2014–2024
Table 04: U.S. Uterine Fibroid Treatment Market Size (US$ Mn) Forecast, by Myomectomy Procedure Type, 2014–2024
Table 05: U.S. Uterine Fibroid Treatment Market Value (US$ Mn) Forecast, by End-user, 2014–2024
Table 06: U.S. Uterine Fibroid Treatment Market Forecast, by Procedure Type, 2010–2024

U.S. Uterine Fibroids Market: Snapshot

The uterine fibroid treatment market is driven by growing number of hysterectomy surgeries every year in the country. Furthermore, the rising coverage of healthcare and increasing prevalence of non-cancerous tumors in women of childbearing age is expected to be the most vital reason for expansion of the uterine fibroids market growth. Now a days, fibroids are an important public health concern, due of the large number of women affected by the problem and the large number of hysterectomy procedure are done to treat the symptoms. 

The National Institute of Health (NIH) conducts research on uterine fibroids, supports studies of fibroids at academic institutions, and sponsors interdisciplinary conferences where researchers share and discuss the results of their studies. Medical therapy is used for many women who have symptoms from fibroids and sometimes is used prior to surgery to shrink the fibroids. Commercially available drugs that shrink fibroids include gonadotropin-releasing hormones, which usually cause symptoms of menopause. Drugs that block the hormone progesterone can slow or stop the growth of fibroids. Some health care providers may use hormonal or over-the-counter medications to control pain and bleeding. 

U.S. Uterine Fibroids Market: Trends and Opportunities

According to the U.S. Department of Health and Human Services Office on Women’s Health, about 30 percent of all women will get them by age 35, and around 20-80 percent of women will do so by age 50. For some reason, African American women are more likely to experience fibroids, and to do so at a younger age. As women age, fibroid growth rates decline for most women, but not for African American women. Several treatment options are available now a days, which are driving the overall uterine fibroids market such as self-help techniques, drug therapy, uterine artery embolization and less invasive surgical procedures (myomectomy & hysterectomy). 

The report is a combination of primary and secondary research. Primary research formed the bulk of our research efforts, with information collected from telephonic interviews and interactions via e-mail. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various national and international databases. The report provides market size in terms of US$ Mn for each segment for the period from 2016 to 2024, considering the macro and micro-environmental factors. Growth rates for each segment within the U.S uterine fibroids market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, vaccination expenditure, and regulatory requirements. 

U.S. Uterine Fibroids Market: Drivers and Restraints

The market overview section of the report includes qualitative analysis of the overall uterine fibroids market including the determining factors and market dynamics such as drivers, restraints, market trends and opportunities, along with white space analysis. In addition, market attractiveness analysis by country and end-user along with competitive landscape by key players have been provided which explain the intensity of competition in the market. The competitive scenario between market players has been evaluated through market share analysis. These factors would help the market players take strategic decisions in order to strengthen their positions and increase their shares in the global market. Pricing analysis holds a crucial part of the report, which further describes the cost to end-user and cost to patient.

The market is driven by changing prevalence of cancerous tumors. The market is projected to grow due to increasing investment in healthcare sector. In terms of distribution channel segment orthopedic clinics is projected to expand at a high CAGR on the backdrop of growing investment healthcare during sports injuries. The hospitals and ambulatory surgical center segment are expected to expand at a significant CAGR over the forecast period. 

Geographically, the U.S uterine fibroids market is showing a substantial growth due to increasing direct and indirect investments by the government and other private companies. Increasing investments and penetration by key market players globally are expected to drive the uterine fibroids market during the forecast period. 

Key Players Mentioned in the Report are:

Key companies profiled in the report include Blue Endo, Richard Wolf Medical Instruments, Boston Scientific Corporation, Cooper Surgical, Halt Medical, Inc., Karl Storz, LiNA Medical USA, Merit Medical Systems, Olympus Corporation, Richard Wolf GmbH and Halt Medical, Inc. 

The orthopedic braces & supports, casting and splints market has been segmented as follows:

  • Procedure Type
    • Endometrial Ablation
    • MRI Guided Procedures
    • Hysterectomy
    • Myomectomy
    • Uterine Artery Embolization
    • Radiofrequency Ablation
    • Others
  • Procedure Sub Type
    • MRI Guided Procedures
      • MRI-guided Percutaneous Laser Ablation
      • MRI Guided Transcutaneous Focused Ultrasound
    • Hysterectomy
      • Abdominal Hysterectomy
      • Vaginal Hysterectomy
      • Laparoscopic Hysterectomy
      • Robotic Hysterectomy
      • Hysteroscopic Morcellation
    • Myomectomy
      • Open Myomectomy
      • Laparoscopic Myomectomy
      • Robotic Myomectomy

U.S. Uterine Fibroid Treatment Market, by End User

  • Hospitals
  • Ambulatory Surgical Centers

U.S. Uterine Fibroid Treatment Market, by Geography

  • U.S.


 
 
Back To Top